Literature DB >> 25876206

We should prohibit warfarin in idiopathic pulmonary fibrosis.

Khuder Alagha1, Veronique Secq, Laurie Pahus, Tunde Sofalvi, Alain Palot, Arnaud Bourdin, Pascal Chanez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25876206     DOI： 10.1164/rccm.201412-2281LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

Review 1.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

2.  Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Syeda Fatima Naqvi; Amir Humza Sohail; Dhairya A Lakhani; James Maurer; Sarah Sofka; Yousaf B Hadi
Journal:  Pulm Med       Date:  2021-11-25

Review 3.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.